Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;48(3):513-521.
doi: 10.1007/s10900-023-01195-8. Epub 2023 Feb 3.

High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia

Kiran Paudel  1   2 , Sana Gupta  2 , Kamal Gautam  2 , Jeffrey A Wickersham  3   4 , Antoine Khati  2 , Iskandar Azwa  4   5 , Toan Ha  6 , Roman Shrestha  7   8   9   10
Affiliations

High Interest in Long-acting Injectable Pre-exposure Prophylaxis (LAI-PrEP) for HIV Prevention Among Men Who Have Sex With Men (MSM): Result From A Nationwide Survey in Malaysia

Kiran Paudel et al. J Community Health. 2023 Jun.

Abstract

The recent approval of long-acting injectable cabotegravir (CAB-LA) as PrEP for HIV prevention could be an attractive alternative for MSM, particularly among those who face barriers to adherence using the oral pill. This study reports on the awareness of long-acting injectable PrEP (LAI-PrEP) and factors associated with interest in LAI-PrEP use among a nationwide sample of MSM in Malaysia. An online cross-sectional survey was conducted between August and September 2021 to explore perspectives on PrEP modalities among Malaysian MSM (N = 870). Convenience sampling was used to recruit participants using ads on two platforms hornet and facebook. While only 9.1% of the study participants were aware of LAI-PrEP, the majority had heard of oral PrEP (80.9%). After giving a description of it, a large majority (86.6%) expressed interest in using it if made accessible. Those who had a prior history of HIV testing (aOR = 1.9; 95% CI = 1.2-3.2) were more likely to use LAI-PrEP. Interestingly, despite the concerns related to potential high cost (aOR = 3.4; 95% CI = 2.1-5.5) and long-term side effects (aOR = 1.9; 95% CI = 1.2-3.1), the majority of the participants were interested in using LAI-PrEP. Those who were afraid of (or disliked) syringes were less interested in using it (aOR = 0.2; 95% CI; 0.1-0.4). In the recent context that LAI-PrEP was shown to be safe and effective at preventing HIV, our results indicate its potential relevance as an additional PrEP option that could accelerate the uptake and scale-up of PrEP. However, it is crucial to conduct future research urgently to improve the understanding of strategies that could enhance the accessibility, acceptability, and affordability of LAI-PrEP for MSM in low- and middle-income countries, including Malaysia.

Keywords: HIV; Malaysia; Pre-exposure prophylaxis (PrEP); cabotegravir; long-acting injectable PrEP (LAI-PrEP); men who have sex with men (MSM).

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Authors have no competing interest associated with this paper.

Figures

Fig. 1
Fig. 1
Concerns related to LAI-PrEP among study participants (N = 870)
See this image and copyright information in PMC

References

    1. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, & Gill ON (2016). Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. The Lancet, 387(10013), 53–60. 10.1016/S0140-6736(15)00056-2 - DOI - PMC - PubMed
    1. WHO_HIV_2015.48_eng.pdf.(n.d.).Retrievedfrom https://apps.who.int/iris/bitstream/handle/10665/197906/WHO_HIV_2015.48_...
    1. Agrahari V, Anderson SM, Peet MM, Wong AP, Singh ON, Doncel GF, & Clark MR (2022). Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. Expert opinion on drug delivery, 19(10), 1365–1380. 10.1080/17425247.2022.2135699 - DOI - PMC - PubMed
    1. Flash C, Krakower D, & Mayer KH. (2012). The Promise of Antiretrovirals for HIV Prevention. Current infectious disease reports, 14(2), 185–193. 10.1007/s11908-012-0242-z - DOI - PMC - PubMed
    1. Schmidt HA, Rodolph M, Schaefer R, Baggaley R, & Doherty M (2022). Long-acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice. Journal of the International AIDS Society, 25(7), e25963. 10.1002/jia2.25963 - DOI - PMC - PubMed

Publication types

Substances